For decades, cancer immunotherapy has focused primarily on CD8+ cytotoxic T lymphocytes as the main executors of tumor cell ...
Researchers at the Kennedy Institute of Rheumatology have found that physically resisting the formation of an immunological synapse actually promotes a stronger immune response. The findings could ...
CD4+ T cells, long regarded as supporting actors in cancer immunity, are emerging as central regulators of tumor control and ...
A phase 3 study of eftilagimod alfa for NSCLC is ending early due to futility, according to an update from developer Immutep.
Independent Data Monitoring Committee Recommends Discontinuation of Phase III Trial Following Futility AnalysisSYDNEY, AUSTRALIA, March 13, 2026 ...
Australian biotech investors received a brutal reminder of the sector’s binary risk on Friday, as Immutep Ltd (ASX:IMM) ...
Independent Data Monitoring Committee Recommends Discontinuation of Phase III Trial Following Futility Analysis SYDNEY, AUSTRALIA, March 13, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: ...
A multi-disciplinary research team at the Wyss Institute at Harvard University, Dana-Farber Cancer Institute, and ...
The COVID-19 pandemic brought messenger RNA (mRNA) vaccines to the forefront of global health care. After their clinical ...
Wyss Institute's DoriVac combined vaccine and adjuvant technology uses nanoscale precision enabled by DNA origami to induce broad immunity against ...
The COVID-19 pandemic brought messenger RNA (mRNA) vaccines to the forefront of global health care. After their clinical trial stages, the first COVID-19 mRNA vaccine was administered on 8 December ...
A futuristic “DNA origami” vaccine platform may one day outperform mRNA shots while being easier to produce and distribute. Credit: Shutterstock Scientists have developed a new DNA origami–based ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results